New product newswire: March 5, 2007

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors.

The new approval is for a first-in-class TRPM8 receptor agonist to stimulate corneal sensory nerves to increase natural tear production.

The replacement therapy is indicated for patients 5 years and older, marking the first approval for an oral solution form of hydrocortisone.